CoChat

The effect of addition of liraglutide to high‐dose intensive insulin therapy: a randomized prospective trial

Lane, W., Weinrib, S., Rappaport, J., Hale, C. · 2014 · Diabetes, Obesity and Metabolism
Cited by 91

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Aims: Patients with type 2 diabetes and insulin resistance may require high insulin doses to control hyperglycaemia. The addition of glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RA s) to basal insulin therapy has been shown to reduce insulin requirement while reducing insulin‐associated weight gain [1,2]. The effect of GLP ‐1 RA therapy added to intensive (basal/bolus) insulin therapy has not been studied in a prospective trial. This trial evaluated the effect of the addition of liraglutide to high‐dose intensive insulin therapy compared with standard insulin up‐titration in obese insulin‐resistant patients with type 2 diabetes requiring high‐dose insulin therapy. Methods: Thirty‐seven subjects with type 2 diabetes requiring >100 units of insulin daily administered either by continuous subcutaneous insulin infusion ( CSII ) or by multiple daily injections ( MDIs ) with or without metformin were randomized to receive either liraglutide plus insulin (LIRA) or intensive insulin only (controls). Liraglutide was initiated at 0.6 mg subcutaneously (sq) per day and increased to either 1.2 or 1.8 mg daily in combination with intensive insulin therapy. Controls received intensive insulin up‐titration only. Results: At 6 months, subjects receiving liraglutide plus insulin experienced statistically significant reductions in HbA1c , weight, insulin dose and glycaemic variability (GV) by continuous glucose monitor ( CGM ) compared with the control group receiving insulin only. Conclusions: Adding liraglutide to intensive high‐dose (basal/bolus) insulin therapy results in greater improvement in glycaemic control than insulin therapy alone, with additional benefits of weight loss and reduced GV.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12286

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Lane, W., Weinrib, S., Rappaport, J., & Hale, C.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2014-03-25
Volume
16
Issue
9
Pages
827-832
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2157354650
Cited by
91
References
2
FWCI
9.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.